Elucidating the role of procalcitonin as a biomarker in hospitalized COVID-19 patients
Copyright © 2022 Elsevier Inc. All rights reserved..
Our objectives were to evaluate the role of procalcitonin in identifying bacterial co-infections in hospitalized COVID-19 patients and quantify antibiotic prescribing during the 2020 pandemic surge. Hospitalized COVID-19 patients with both a procalcitonin test and blood or respiratory culture sent on admission were included in this retrospective study. Confirmed co-infection was determined by an infectious diseases specialist. In total, 819 patients were included; 335 (41%) had an elevated procalcitonin (>0.5 ng/mL) and of these, 42 (13%) had an initial bacterial co-infection. Positive predictive value of elevated procalcitonin for co-infection was 13% while the negative predictive value was 94%. Ninety-six percent of patients with an elevated procalcitonin received antibiotics (median 6 days of therapy), compared to 82% with low procalcitonin (median 4 days of therapy) (adjusted OR:3.3, P < 0.001). We observed elevated initial procalcitonin in many COVID patients without concurrent bacterial co-infections which potentially contributed to antibiotic over-prescribing.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:103 |
|---|---|
| Enthalten in: |
Diagnostic microbiology and infectious disease - 103(2022), 4 vom: 19. Aug., Seite 115721 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cowman, Kelsie [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9007-12-9 |
|---|
| Anmerkungen: |
Date Completed 12.07.2022 Date Revised 21.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.diagmicrobio.2022.115721 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM341581518 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM341581518 | ||
| 003 | DE-627 | ||
| 005 | 20231226012118.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.diagmicrobio.2022.115721 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1138.xml |
| 035 | |a (DE-627)NLM341581518 | ||
| 035 | |a (NLM)35635888 | ||
| 035 | |a (PII)S0732-8893(22)00087-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cowman, Kelsie |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Elucidating the role of procalcitonin as a biomarker in hospitalized COVID-19 patients |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.07.2022 | ||
| 500 | |a Date Revised 21.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Elsevier Inc. All rights reserved. | ||
| 520 | |a Our objectives were to evaluate the role of procalcitonin in identifying bacterial co-infections in hospitalized COVID-19 patients and quantify antibiotic prescribing during the 2020 pandemic surge. Hospitalized COVID-19 patients with both a procalcitonin test and blood or respiratory culture sent on admission were included in this retrospective study. Confirmed co-infection was determined by an infectious diseases specialist. In total, 819 patients were included; 335 (41%) had an elevated procalcitonin (>0.5 ng/mL) and of these, 42 (13%) had an initial bacterial co-infection. Positive predictive value of elevated procalcitonin for co-infection was 13% while the negative predictive value was 94%. Ninety-six percent of patients with an elevated procalcitonin received antibiotics (median 6 days of therapy), compared to 82% with low procalcitonin (median 4 days of therapy) (adjusted OR:3.3, P < 0.001). We observed elevated initial procalcitonin in many COVID patients without concurrent bacterial co-infections which potentially contributed to antibiotic over-prescribing | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Antimicrobial stewardship | |
| 650 | 4 | |a Bacterial co-infection | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Procalcitonin | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Procalcitonin |2 NLM | |
| 650 | 7 | |a Calcitonin |2 NLM | |
| 650 | 7 | |a 9007-12-9 |2 NLM | |
| 650 | 7 | |a Calcitonin Gene-Related Peptide |2 NLM | |
| 650 | 7 | |a JHB2QIZ69Z |2 NLM | |
| 700 | 1 | |a Rossi, James |e verfasserin |4 aut | |
| 700 | 1 | |a Gendlina, Inessa |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Sichen |e verfasserin |4 aut | |
| 700 | 1 | |a Szymczak, Wendy |e verfasserin |4 aut | |
| 700 | 1 | |a Forest, Stefanie K |e verfasserin |4 aut | |
| 700 | 1 | |a Wolgast, Lucia |e verfasserin |4 aut | |
| 700 | 1 | |a Orner, Erika |e verfasserin |4 aut | |
| 700 | 1 | |a Bao, Hongkai |e verfasserin |4 aut | |
| 700 | 1 | |a Cervera-Hernandez, Miguel E |e verfasserin |4 aut | |
| 700 | 1 | |a Ceniceros, Ashley |e verfasserin |4 aut | |
| 700 | 1 | |a Thota, Raja |e verfasserin |4 aut | |
| 700 | 1 | |a Pirofski, Liise-Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Nori, Priya |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Diagnostic microbiology and infectious disease |d 1986 |g 103(2022), 4 vom: 19. Aug., Seite 115721 |w (DE-627)NLM01262845X |x 1879-0070 |7 nnns |
| 773 | 1 | 8 | |g volume:103 |g year:2022 |g number:4 |g day:19 |g month:08 |g pages:115721 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.diagmicrobio.2022.115721 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 103 |j 2022 |e 4 |b 19 |c 08 |h 115721 | ||